Results 191 to 200 of about 1,428,219 (313)

Analog Front-End ASIC for Compact Silicon Photomultiplier Sensor Interfaces in Mixed-Signal Systems. [PDF]

Sensors (Basel)
Badoni D, Ammendola R, Bocci V, Chiodi G, Iacoangeli F, Pasta S, Rebustini G, Recchia L.   +7 more
europepmc   +1 more source

Fast timing with induced current detectors

Nuclear Instruments and Methods in Physics Research Section A : Accelerators, Spectrometers, Detectors and Associated Equipment, 2019
R. Lipton, Jason Theiman
semanticscholar   +1 more source

Measurements of timing resolution of ultra-fast silicon detectors with the SAMPIC waveform digitizer [PDF]

, 2016
D. Breton, Victor de Cacqueray, 'Eric Delagnes, H. Grabas, J. Maalmi, N. Minafra, C. Royon, M. Saimpert   +7 more
semanticscholar   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

The Effects of High-Energy Carbon Co-Doping on IMB-CNM LGAD Fabrication and Performance. [PDF]

Sensors (Basel)
Villegas J, Dougados F, Torres C, Fernandez-Martinez P, Jiménez-Ramos MDC, Hidalgo S.   +5 more
europepmc   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Constraining the impact of chlorine as a neutron absorber in next-gen fast reactor designs. [PDF]

Sci Rep
Hanselman K, Allan IJ, Kuvin SA, Kawano T, Kleedtke N, Lee HY, Paneru SN, Thompson N, Winkelbauer J, Cisneros T, Harper B, Wargon M.   +11 more
europepmc   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Development of a Prototype AWSM-PET Device for Augmented Whole-Body PET Imaging and Initial Human Study. [PDF]

J Nucl Med
Chen Y, Mintzer RA, Cho S, Pocci D, Hamdi M, Komarov S, Cai L, Aggarwal S, Thomas A, Corbeil J, Frye J, Dehdashti F, O'Sullivan JA, Laforest R, Siegel SB, Tai YC.   +15 more
europepmc   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source